VitaSpring Biomedical Co. Ltd. (VSBC) stock
VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical gross margin
Gross margin is gross profit as a percentage of revenue.
VitaSpring Biomedical's gross margin for the twelve months ending Oct 31, 2022 was 40.9%. For fiscal 2022 it was 36.8%, against 45.2% the year before. The highest annual figure on record is 79.8% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Jan 31, 2022 | 36.8% | −8.4 |
| FY2021 | Jan 31, 2021 | 45.2% | +34.0 |
| FY2020 | Jan 31, 2020 | 11.2% | −68.7 |
| FY2019 | Jan 31, 2019 | 79.8% | +10.0 |
| FY2018 | Jan 31, 2018 | 69.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2023CQ1 2022 | Apr 30, 2022 | 38.1% | −6.8 |
| Q4 FY2022CQ4 2021 | Jan 31, 2022 | 42.0% | −3.2 |
| Q3 FY2022CQ3 2021 | Oct 31, 2021 | 10.0% | +125.0 |
| Q2 FY2022CQ2 2021 | Jul 31, 2021 | 24.5% | −62.9 |
| Q1 FY2022CQ1 2021 | Apr 30, 2021 | 44.9% | −43.0 |
| Q4 FY2021CQ4 2020 | Jan 31, 2021 | 45.2% | −40.1 |
| Q4 FY2020CQ4 2019 | Jan 31, 2020 | -115.0% | −194.4 |
| Q1 FY2020CQ1 2019 | Apr 30, 2019 | 87.5% | +9.3 |
| Q4 FY2019CQ4 2018 | Jan 31, 2019 | 87.9% | +11.5 |
| Q3 FY2019CQ3 2018 | Oct 31, 2018 | 85.3% | −0.6 |
| Q2 FY2019CQ2 2018 | Jul 31, 2018 | 79.4% | +40.3 |
| Q1 FY2019CQ1 2018 | Apr 30, 2018 | 78.2% | −6.0 |
| Q4 FY2018CQ4 2017 | Jan 31, 2018 | 76.5% | – |
| Q3 FY2018CQ3 2017 | Oct 31, 2017 | 85.9% | – |
| Q2 FY2018CQ2 2017 | Jul 31, 2017 | 39.1% | – |
| Q1 FY2018CQ1 2017 | Apr 30, 2017 | 84.2% | – |
See a number that looks wrong?